Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led many centers, for reasons of efficiency, to prioritize tumor necrosis factor inhibitors (TNFi) as first-line therapy. Data on whether prior exposure to TNFi may affect the drug survival of IL17i and IL23i therapies are lacking. Using data from the Biobadaderm registry, we compared treatment persistence among patients with psoriasis who received IL17i or IL23i as first-line therapy and those who received these agents after prior TNFi treatment. Rates of treatment discontinuation and adverse events (AEs) were compared between groups. Results showed that overall drug survival was higher in patients treated first line with IL17i or IL23i vs those treated after TNFi exposure. However, no significant differences were observed between groups in treatment discontinuation due to inefficacy or serious AEs. Overall AE rates were similar, with no differences in serious AEs or serious infections. Although global AE rates and discontinuation due to AEs were higher in patients previously on TNFi who subsequently received IL17i or IL23i vs biologic-naïve patients, these differences did not reach statistical significance. In conclusion, this study suggests that prior exposure to TNFi may influence the persistence of IL17i and IL23i therapies in patients with psoriasis.

Authors

Institutions

Publication Details

Journal
Actas Dermo-Sifiliográficas
Published
2025-12-31
DOI
https://doi.org/10.1016/j.ad.2025.104588
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Diana Ruíz Genao, E. Daudén, Mónica Roncero Riesco, José Carlos Ruiz Carrascosa et al.
Actas Dermo-Sifiliográficas
Psoriasis: Treatment and Pathogenesis
article

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

Diana Ruíz Genao, E. Daudén, Mónica Roncero Riesco, José Carlos Ruiz Carrascosa, P. de la Cueva Dobao, Isabel Martínez Belinchón, Lopez-Estebaranz José-Luis, Alicia González Quesada, Antonio Sahuquillo-Torralba, R.A.Q.U.E.L. RIVERA-DIAZ, Ofelia Baniandrés Rodríguez, Almudena Mateu Puchades, Enrique Herrera Acosta, JM Carrascosa, Miguel Ángel Descalzo, Carmen García-Donoso, Mariano Ara Martín, Lourdes Rodriguez Fernández-Freire, Ignacio García-Doval, MªTeresa Abalde Pintos, Josep Riera-Monroig, Franciso José Gomez Garcia, Marta Ferrán Farres
article en

Abstract

Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led many centers, for reasons of efficiency, to prioritize tumor necrosis factor inhibitors (TNFi) as first-line therapy. Data on whether prior exposure to TNFi may affect the drug survival of IL17i and IL23i therapies are lacking. Using data from the Biobadaderm registry, we compared treatment persistence among patients with psoriasis who received IL17i or IL23i as first-line therapy and those who received these agents after prior TNFi treatment. Rates of treatment discontinuation and adverse events (AEs) were compared between groups. Results showed that overall drug survival was higher in patients treated first line with IL17i or IL23i vs those treated after TNFi exposure. However, no significant differences were observed between groups in treatment discontinuation due to inefficacy or serious AEs. Overall AE rates were similar, with no differences in serious AEs or serious infections. Although global AE rates and discontinuation due to AEs were higher in patients previously on TNFi who subsequently received IL17i or IL23i vs biologic-naïve patients, these differences did not reach statistical significance. In conclusion, this study suggests that prior exposure to TNFi may influence the persistence of IL17i and IL23i therapies in patients with psoriasis.

Actas Dermo-SifiliográficasVol. 117(3)
Universitat de Miguel Hernández d'Elx (ES), Universidad Complutense de Madrid (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Complejo Hospitalario de Salamanca (ES), Hospital Universitario Fundación Alcorcón (ES), Spanish Academy of Dermatology and Venereology (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario Reina Sofía (ES), Hospital Universitario Doctor Peset (ES), Hospital Universitario de La Princesa (ES), Hospital Del Mar (ES), Hospital Clínico Universitario Lozano Blesa (ES), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Complejo Hospitalario de Pontevedra (ES), Hospital Universitario Infanta Leonor (ES), Universitat de Barcelona (ES)
Good health and well-being
Openalex Percentile: Top 35%
Psoriasis: Treatment and Pathogenesis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.